About this trial
Pasteurized Donor Human Milk (PDHM) is recognized as providing vital immunological and nutritional benefits to vulnerable infants. Although PDHM is widely used in neonatal intensive care units (NICUs) to prevent infections (necrotizing enterocolitis) and improve infant health outcomes, its use for other populations, such as HIV-exposed infants, has been minimal.
Pasteurized donor human milk is included in the 2023 Canadian Paediatric Society clinical consensus as a potential way to provide HIV-exposed infants some of the immunological benefits of human milk in a safe manner, as opposed to exclusive formula feeding (which is currently considered the gold standard for HIV-exposed infants). These new consensus guidelines also include recommendations to support those who wish to breastfeed using a harm reduction approach (e.g., increased viral load monitoring by peds infectious diseases), given the low risk of transmission in those adhering to antiretroviral medications. However, mixed feeding (e.g., breastfeeding and provision of infant formula) is not recommended, due to the potential for micro abrasions in the gastrointestinal epithelium as a result of the protein size in infant formula (which is larger and more abrasive than in human milk), which may increase the risk of HIV transmission if the HIV virus is present in breastmilk. As such, donor milk also presents a possible solution to support those who choose to breastfeed, but who may require a temporary supplement for whatever reason (e.g., nipple cracks, mastitis, etc.), as donor milk is human milk, thus has the same size of proteins and does not pose the same risk as infant formula in damaging the epithelial layer in the gut.
Overall, major obstacles remain that prevent newborns outside of the NICU from regularly having access to donor human milk. These obstacles are illustrated by the high cost of donor milk, which is not covered by government programs, and the lack of information about the clinical benefits (for both those who choose to breastfeed or formula feed), acceptability of caregivers for this feeding option, and feasibility of providing donor human milk outside of a hospital setting.
The investigators aim to determine whether giving PDHM to infants exposed to HIV is a practical possibility and learn from caregivers about any challenges associated with this feeding option. The results of this study will guide future research and a potential provincial initiative to expand access to PDHM for this population.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
≥15 years of age
Pregnant or recently gave birth and living with HIV or is the primary caregivers of an HIV-exposed infant
Being followed by SHA Pediatric Infectious Disease
Saskatchewan resident (living within ~150 km from the University of Saskatchewan)
Disqualifiers
None
Trial design
Single group
Treatments tested in this trial
Pasteurized Donor Human Milk
Other interventionThis is a single arm study in which all participants will receive pasteurized donor human milk sourced from the Norther Star Mother's Milk Bank (Calgary, AB, Canada)
Treatment groups
Trial outcomes
Primary outcomes
Frequency of PDHM provision (#/day)
Frequency (# of PDHM feedings/day) of PDHM provided to infants as a top up to infant formula or while breastfeeding
Volume of PDHM provision (mL/day)
Volume (mL/day) of PDHM provided to infants as a top up to infant formula or while breastfeeding
Secondary outcomes
Events of infant intolerance (n, %)
Participant reported events of poor tolerance (including gas, vomiting, diarrhea, etc.) which occur while providing the intervention (PDHM)
Caregiver-related experiences and challenges
Open-ended comments from caregivers regarding any concerns with PDHM provision (such as storage, thawing, preparation, or infant tolerance).
Other outcomes
Infant growth (g/day)
Infant growth (g/d weight gain) from visit 1 to visit 4 (baseline to endline)
Frequency of illness or opportunistic infections (n, %)
Rates of illness or opportunistic infection throughout the intervention period.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.